Scarica l'app Stockscreener
438.34
2.20%
-9.87
Dopo l'orario di chiusura:
436.56
-1.78
-0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$448.21
Aprire:
$444.02
Volume 24 ore:
2.04M
Relative Volume:
0.93
Capitalizzazione di mercato:
$162.90B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
24.10
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
-5.73%
1M Prestazione:
-17.55%
6M Prestazione:
-24.26%
1 anno Prestazione:
+8.25%
Intervallo 1D:
$437.32
$444.95
Intervallo di 1 settimana:
$437.32
$466.79
Portata 52W:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Thermo Fisher Scientific (TMO) Reports Strong Q1 FY2026 Earnings - GuruFocus
Is Thermo Fisher (TMO) Quietly Reinforcing Its End‑to‑End Biopharma Role With New IBTROZI Duties? - simplywall.st
Thermo Fisher (TMO) Coverage Resumed with Sector Perform Rating - GuruFocus
RBC Capital assumes Thermo Fisher stock with Sector Perform rating - Investing.com
RBC Capital assumes Thermo Fisher stock with Sector Perform rating By Investing.com - Investing.com Canada
Ex-Investor Seeks Records On $8.9B Thermo Fisher Payout - Law360
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat with EPS of $5.44 - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Bioinformatics Platforms Market Is Going to Boom | • Illumina Inc • Thermo Fisher Scientific Inc • QIAGEN N.V - openPR.com
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Cell Cryopreservation Market 2026- 2033 Overview: Share, Size, - openPR.com
Thermo Fisher Scientific stock (US8835561023): Q1 earnings beat signals strength in life sciences - AD HOC NEWS
Can Mettler-Toledo International Outrun Thermo Fisher Scientific in the Next Rally? - Trefis
Between Mettler-Toledo International and Thermo Fisher Scientific, Which Stock Looks Set to Break Out? - Trefis
Thermo Fisher (TMO) Completes Tech Transfer for Ibtrozi - GuruFocus
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment - Moomoo
Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market - MarketWatch
Nuvation Bio partners with Thermo Fisher for US drug manufacturing - Investing.com
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Thermo Fisher Sci. stock (US8835561023): Recent earnings beat and price gain - AD HOC NEWS
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Sci. stock (US8835561023): Leader in life sciences tools - AD HOC NEWS
Nucleic Acid Isolation and Purification Market Report 2026-2030: Trends, Challenges and Competitive Analysis Featuring Thermo Fisher Scientific, Merck, QIAGEN, and Roche - Yahoo Finance
Westpac Banking Corp's Thermo Fisher Scientific Inc(TMO) Holding History - GuruFocus
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Cash Flow – TSX:TMO - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S - TradingView
Thermo Fisher Scientific Inc. Shs Unsponsored Canadian Depoitary Receipt Hedged Reg S Balance Sheet – TSX:TMO - TradingView
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Thermo Fisher Expands Cell Therapy And Hydration Platforms To Deepen Ecosystem - Yahoo Finance
Thermo Fisher Scientific : Additional Soliciting Materials - marketscreener.com
Thermo Fisher Sci. stock (US8835561023): Q1 2026 earnings beat estimates - AD HOC NEWS
Upstream Bioprocessing Equipment Market Is Going to Boom | Thermo Fisher Scientific, Merck KGaA, Sartorius AG - openPR.com
Thermo Fisher Scientific Inc (TMO): An Investor Outlook with Strong Buy Ratings and Robust Revenue Growth - DirectorsTalk Interviews
Cross-Belt Analyzers Market Size Accelerating at 8.7% CAGR | - openPR.com
Thermo Fisher Scientific acquires Clario for nearly $8.9bn - MSN
Thermo Fisher Sci. stock (US8835561023): Earnings beat and guidance lift drive shares higher - AD HOC NEWS
Jim Cramer on Thermo Fisher: “I Think You Can Buy It at This Level” - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market - MarketWatch
Wells Fargo Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $615 - Moomoo
Thermo Fisher Scientific Launches PackEye™ XS Radiation Detection Backpack: Covert, High-Accuracy Identification in a Lightweight, Mission-Ready Design - AZoSensors
Polystyrene Latex Particle Market Size Advancing at 6.3% CAGR | - openPR.com
Morgan Stanley, Thermo Fisher, Blue Owl Technology Finance and more on CNBC's 'Final Trades' - MSN
Is It Time To Revisit Thermo Fisher Scientific (TMO) After This Year’s Share Price Pullback - Yahoo Finance
Thermo Fisher Scientific Inc. stock rises Wednesday, still underperforms market - MarketWatch
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider - PharmiWeb.com
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials - BioSpace
Thermo Fisher projects 2026 adjusted EPS of $24.64-$25.12 as it raises revenue outlook to $47.3B-$48.1B - MSN
Erste Group Maintains Thermo Fisher Scientific(TMO.US) With Hold Rating - Moomoo
Billionaire investor takes new stake in Thermo Fisher Scientific - MSN
Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract Pharma
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):